William Damsky MD, PhD

@billdamsky

Academic derm and dermpath at Yale. Sarcoidosis, granulomas, melanoma immunotherapy, inflammatory skin disease, targeted therapy. Aspiring immunologist.

New Haven, CT
Vrijeme pridruživanja: veljača 2019.

Tweetovi

Blokirali ste korisnika/cu @billdamsky

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @billdamsky

  1. proslijedio/la je Tweet
    29. sij

    Thank you to Dr. Michael Girardi for presenting at this week’s Grand Rounds. Dr. Girardi addressed drug synergy in cutaneous t-cell

    Poništi
  2. proslijedio/la je Tweet
    29. sij

    A new review in . led by Dr. Jonathan Leventhal highlights the increasing number of dermatologic toxicities in women receiving therapy.

    Poništi
  3. proslijedio/la je Tweet
    30. sij

    Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib

    Poništi
  4. 25. sij

    Congrats to and colleagues from the Chen lab at Yale on their recent article: identifying VISTA (PD-1H) as a promising treatment target in ... also featured by :

    Poništi
  5. proslijedio/la je Tweet
    24. sij

    . and on the dermatologist who made a tough call that saved a life and points to a way of treating a dangerous condition called DRESS.

    Poništi
  6. proslijedio/la je Tweet
    24. sij

    Congrats to Dr. King and co-author for using JAK inhibitors to treat a severe case of DRESS. Privileged to be a part of the report published JAAD Case Reports.

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    23. sij

    It's out! Our JAKi study for inflammatory skin fibrosis! Awesome collaboration with and all the authors not yet on Twitter!

    Poništi
  8. 23. sij

    New paper from the Nagao lab - treatment of pt w/ DRESS/DIHS with JAK inihb (plus single cell RNAseq data!): consistent with our recent report (2 addnl patients): clearly more work needed, but exciting!

    Poništi
  9. proslijedio/la je Tweet
    19. sij

    Rep. Ayanna Pressley opened up about living with alopecia and revealed that she was now bald. “I want to be free,” Ms. Pressley said. 

    Poništi
  10. 18. sij

    Demodex mite - caught red handed in a patient with pustular rosacea at Saturday clinic

    Poništi
  11. proslijedio/la je Tweet
    16. sij

    Register for the 4th annual and Day - May 20, 2020! 💜 Accepting abstracts for oral and poster presentations now, info on the registration postcard:

    Poništi
  12. proslijedio/la je Tweet
    15. sij

    Recently, a PhD student wrote her dissertation about the experiences of people living with sarcoidosis. She explores their quality of life by conducting interviews. Research initiatives that showcase patient voices are crucial in improving patient care.

    Poništi
  13. proslijedio/la je Tweet
    16. sij

    Extracorporeal photopheresis has been an effective treatment for graft-versus-host disease. In this case, it was used to treat a patient with severe autoimmune colitis induced by checkpoint-inhibitor therapy for melanoma.

    Poništi
  14. 13. sij

    Porokeratosis can be caused by mevalonate pathway (cholesterol synthesis) mutations. new report from - showing that modulation of pathway defects with topical cholesterol / statin combo is a novel treatment for porokeratosis.

    Poništi
  15. 12. sij
    Poništi
  16. 11. sij

    Our latest report looking at JAK inhibition in in open rheum, now online

    Poništi
  17. proslijedio/la je Tweet
    10. sij

    NINJA: an inducible genetic model for creating neoantigens in vivo

    Poništi
  18. proslijedio/la je Tweet
    10. sij

    Article by and Brett King about JAK inhibitors for chilblain

    Poništi
  19. proslijedio/la je Tweet
    10. sij
    Poništi
  20. 7. sij

    verruciform xanthoma. oral lesions most common on the gingival mucosa according to this new series of > 200 cases. . VX is often caused by somatic NSDHL mutations. Same mutation as CHILD syndrome, which can have VX as a feature.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·